Antithrombotic therapy in acute coronary syndromes: Key notes from ESSENCE and TIMI 11B

Seminars in Hematology

Volumn 38, Issue 2 SUPPL. 5, 2001, Pages 67-74

  Fox, Keith A A ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT CARE; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0034959723     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0037-1963(01)90100-3     Document Type: Article

References (44)

1. Optimizing the treatment of unstable angina
2. The ENACT study: A pan-European survey of acute coronary syndromes
3. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry in patients with unstable angina
4. The pathogenesis of coronary artery disease and the acute coronary syndromes
5. Tissue-factor antigen and activity in human coronary atherosclerotic plaques
6. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques
7. Activation of blood coagulation by plaque rupture: Mechanisms and prevention
8. Low-molecular-weight heparins: An intriguing new twist with profound implications
9. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction
10. The Thrombolysis in Myocardial Infarction (TIMI) Trial: Phase I findings
11. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina
12. Aspirin, heparin, or both to treat unstable angina
13. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina
14. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
15. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary endpoints analysis from the ATACS Trial
16. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis
17. Factors associated with failure of medical therapy in patients with unstable angina and non-Q wave myocardial infarction. A TIMI-IIIB database study
18. Guide to anticoagulant therapy, part 1: Heparin
19. Low molecular weight heparin
20. Comparison of efficacy of low molecular weight heparin (parnaparin) with that of unfractionated heparin in the presence of activated platelets in healthy subjects
21. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes
22. Reactivation of unstable angina after the discontinuation of heparin
23. Mechanisms for the antithrombotic activity in man of low molecular weight heparin (LMWHs)
24. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
25. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease
26. Enoxapatin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardia infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial
27. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B/ESSENCE meta-analysis
28. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomized trial
29. Economic assessment of LMWH (enoxaparin) versus UFH in acute coronary syndrome patients: Results from the ESSENCE randomized trial
30. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction
31. One-year follow-up of the ESSENCE trial (enoxaparin versus heparin in unstable angina and non-Q-wave myocardial infarction)
32. Low-molecular-weight heparins: Pharmacologic profile and product differentiation
33. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
34. Low molecular weight heparins in the management of unstable angina/non-Q-wave myocardial infarction
35. Low-molecular-weight heparin during instability in coronary artery disease
36. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC)
37. The mode of action of heparin in plasma
38. The mode of action of low molecular weight heparin preparation (PK10169) and two of its major components on thrombin generation in plasma
39. Randomised placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
40. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization
41. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
42. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
43. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina